Mobile

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with the addition of a licensed drug (Glimepiride) in patients with Type 2 Diabetes

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002309-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

After 54 weeks, to assess the A1C-lowering efficacy of MK-3102 compared to glimepiride. To assess the safety and tolerability of MK-3102.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens